

.....  
(Original Signature of Member)

118TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To direct the Secretary of Defense to establish a grant program for using psychedelic substances to treat certain conditions, and for other purposes.

\_\_\_\_\_  
IN THE HOUSE OF REPRESENTATIVES

Mr. CRENSHAW introduced the following bill; which was referred to the  
Committee on \_\_\_\_\_

\_\_\_\_\_  
**A BILL**

To direct the Secretary of Defense to establish a grant program for using psychedelic substances to treat certain conditions, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Douglas ‘Mike’ Day  
5 Psychedelic Therapy to Save Lives Act of 2023”.

1 **SEC. 2. GRANT PROGRAM OF THE DEPARTMENT OF DE-**  
2 **FENSE TO STUDY TREATMENT OF CERTAIN**  
3 **CONDITIONS USING CERTAIN PSYCHEDELIC**  
4 **SUBSTANCES.**

5 (a) **ESTABLISHMENT.**—Not later than 90 days after  
6 the date of enactment of this Act, the Secretary of Defense  
7 shall award grants to eligible entities to conduct research  
8 on the treatment of members of the Armed Forces serving  
9 on active duty with a covered condition using covered psy-  
10 chedelic substances. Not later than 60 days after the date  
11 of the enactment of this Act, the Secretary shall designate  
12 a lead administrator to carry out the grant program under  
13 this section.

14 (b) **ELIGIBLE ENTITIES.**—The Secretary may award  
15 a grant under this section to any of the following:

16 (1) A department or agency of the Federal Gov-  
17 ernment or a State government.

18 (2) An academic institution.

19 (3) A nonprofit entity.

20 (c) **USE OF GRANT FUNDS.**—A recipient of a grant  
21 awarded under this section may use the grant to—

22 (1) conduct one or more phase two clinical  
23 trials for the treatment of covered conditions that—

24 (A) include members of the Armed Forces  
25 serving on active duty as participants in the  
26 clinical trial; and

1 (B) use individual or group therapy as-  
2 sisted by covered psychedelic substances; or

3 (2) train practitioners to provide treatment to  
4 members of the Armed Forces serving on active duty  
5 for covered conditions using covered psychedelic sub-  
6 stances.

7 (d) PARTICIPATION IN CLINICAL TRIALS.—The Sec-  
8 retary shall authorize any member of the Armed Forces  
9 diagnosed with a covered condition to participate in a clin-  
10 ical trial that is conducted using a grant awarded under  
11 this section or funds provided under subsection (e) and  
12 is authorized pursuant to section 505 of the Federal Food,  
13 Drug, and Cosmetic Act (21 U.S.C. 355), without regard  
14 to—

15 (1) whether the clinical trial involves a sub-  
16 stance included in the schedule under section 202 of  
17 the Controlled Substances Act (21 U.S.C. 812); or

18 (2) section 912a of title 10, United States Code  
19 (article 112a of the Uniform Code of Military Jus-  
20 tice).

21 (e) ADDITIONAL AUTHORITY.—In addition to award-  
22 ing grants under this section, the Secretary shall provide  
23 funds for a clinical research trial using covered psychedelic  
24 substances that is authorized pursuant to section 505 of  
25 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

1 355) and includes members of the Armed Forces as par-  
2 ticipants in the trial.

3 (f) REPORT REQUIRED.—Not later than 180 days  
4 after the date of the enactment of this Act, and every 180  
5 days thereafter, the Secretary shall submit to the Commit-  
6 tees on Armed Services of the House of Representatives  
7 and the Senate a report on grants awarded under this sec-  
8 tion, including the following:

9 (1) Identification of clinics designated to host  
10 activities under such a grant.

11 (2) A description of entities to whom the Sec-  
12 retary has awarded such a grant.

13 (3) The number of members of the Armed  
14 Forces who participated in a clinical trial described  
15 in subsection (d).

16 (4) Information on the findings of such clinical  
17 trials.

18 (g) AUTHORIZATION OF APPROPRIATIONS.—There is  
19 authorized to be appropriated to the Secretary to carry  
20 out this section \$15,000,000 for each of fiscal years 2024  
21 through 2028.

22 (h) DEFINITIONS.—In this section:

23 (1) The term “covered condition” means any of  
24 the following:

25 (A) Post-traumatic stress.

1 (B) Traumatic brain injury.

2 (C) Chronic traumatic encephalopathy

3 (2) The term “covered psychedelic substances”

4 means any of the following:

5 (A) 3,4-methylenedioxy-methamphetamine

6 (commonly known as “MDMA”).

7 (B) Psilocybin.

8 (C) Ibogaine.

9 (D) 5-Methoxy-N,N-dimethyltryptamine

10 (commonly known as “5-MeO-DMT”).

11 (3) The term “State” has the meaning given

12 such term in section 901 of title 32, United States

13 Code.